RE.GA.IN. redraws the clinical map of gastritis from cause to staging
The Real-world Gastritis Initiative, or RE.GA.IN., closes a long-running gap between pathology, endoscopy, and bedside decision-making in gastritis. Built through more than eight months of international deliberation and finalized in Venice in November 2022, the consensus brings together experts from five continents to update how clinicians define, diagnose, and stage inflammatory disease of the stomach. Its value lies in the breadth of the questions it tackles: what gastritis is, how it is caused, how it is recognized, and why its histologic description should carry prognostic weight rather than remain a descriptive afterthought.
The paper is not a narrow technical addendum to earlier work. It sits on the same historical line as the Sydney classification, the Houston update, the Kyoto Global Consensus, and the Maastricht-Florence meetings, but it pushes the field toward a more integrated clinical frame. Gastritis is treated here as a disease spectrum with consequences that extend beyond mucosal inflammation alone. In practice, that means linking the visible lesion, the underlying driver, and the future risk of cancer or autoimmune injury in one coherent workflow.
Helicobacter pylori remains the dominant environmental trigger
Among the most consequential themes is the central role of Helicobacter pylori. The consensus places the organism not only at the center of environmental gastritis, but also at the center of the gastric oncogenetic field. Clinically, that is a crucial shift in emphasis. H. pylori does more than inflame the lining of the stomach; it helps shape the biologic terrain in which atrophy, intestinal metaplasia, dysplasia, and cancer can emerge over time.
The practical implication is straightforward. A patient with gastritis should not be viewed only through the lens of symptoms or superficial erythema seen at endoscopy. Identification of H. pylori carries prognostic consequences because it identifies a modifiable cause of ongoing mucosal injury. Eradication interrupts the inflammatory stimulus before the mucosa progresses further along the carcinogenic pathway, which is why microbiologic diagnosis and treatment remain fundamental to any modern gastritis strategy.
Autoimmune gastritis and microbiota widen the differential diagnosis
RE.GA.IN. also gives proper attention to gastric autoimmunity. Autoimmune gastritis is biologically distinct from H. pylori-associated disease, even though both can culminate in atrophic change and altered cancer risk. In autoimmune disease, the stomach becomes the target of immune-mediated destruction rather than a passive site of infection-driven injury. That distinction shapes surveillance decisions, laboratory interpretation, and the search for associated autoimmune conditions.
One sentence captures the bedside consequence: not every inflamed stomach is infected, and not every atrophic stomach is driven by the same mechanism.
The consensus extends the field further by addressing the gastric microbiota. This is a more recent and less settled domain, but it matters because the stomach is not sterile in the biologic sense clinicians once assumed. Microbial communities may interact with mucosal immunity, acid suppression, and the local environment created by chronic disease. The report does not turn microbiota into a replacement explanation for established causes, yet it recognizes that the gastric ecosystem may influence the shape and persistence of inflammation. That perspective encourages a broader diagnostic mindset, especially when histology does not fit a single obvious cause.
Endoscopy still depends on histology, but histology must be staged
A recurring theme in the RE.GA.IN. framework is that endoscopy is indispensable, but not sufficient. Modern endoscopic imaging can improve lesion recognition and guide biopsy placement, yet the consensus does not allow visual inspection alone to define the full clinical burden of gastritis. Histology remains the anchor. What changes is the expectation placed on pathology reporting.
Instead of recording inflammation as a simple yes-or-no finding, the report elevates the clinical priority of staging gastritis histologically. Staging matters because it helps translate microscopic injury into risk. The stomach may show active inflammation, atrophy, metaplasia, or combinations of these findings, and each pattern implies a different position on the disease continuum. A report that names gastritis without staging it leaves clinicians with an incomplete risk profile and weakens follow-up planning.
This approach reflects a pathophysiologic reality: chronic gastric injury evolves over time, and the probability of neoplastic transformation depends on both cause and extent of mucosal remodeling. In that setting, staging is not clerical detail. It is the bridge between biopsy and prognosis.
A consensus built for real-world clinical practice
The consensus process itself was deliberately multidisciplinary. Experts debated the most controversial issues in the gastritis spectrum and then distilled their conclusions into patient-centered, evidence-based statements. That format matters because gastritis is encountered across settings that do not always share the same resources, from tertiary pathology services to general gastroenterology clinics. A real-world initiative has to work in that range.
The paper’s scope also reflects a deliberate attempt to move beyond isolated definitions. Epidemiology, causation, autoimmunity, microbiota, endoscopic innovation, and histologic staging are treated as connected parts of one disease model. That integrated structure should help clinicians avoid the common error of managing gastritis as a symptom label rather than as a pathobiologic diagnosis with different etiologies and different downstream risks.
In concrete terms, the RE.GA.IN. recommendations support a more disciplined workflow: identify the cause when possible, distinguish infectious from autoimmune disease, use endoscopy to target tissue sampling, and ask pathology to stage the mucosal injury rather than merely describe it. The result is a more actionable report for the clinician and a more informative record for the patient.
Why this matters for cancer prevention and longitudinal care
The strongest clinical through-line in RE.GA.IN. is the link between gastritis and gastric cancer prevention. H. pylori remains the most important environmental determinant of the gastric oncogenetic field, so early identification and eradication remain central to risk reduction. At the same time, autoimmune gastritis and advanced atrophic remodeling can also signal a stomach that has moved into a higher-risk state. In both settings, histologic staging helps identify who needs closer observation and who may benefit from structured follow-up.
The consensus does not pretend that every unanswered issue is settled. Gastric microbiota remains an evolving area, and the optimal ways to operationalize new endoscopic horizons will depend on local expertise and future validation. Even so, the document provides a practical framework that aligns pathology, endoscopy, and etiologic diagnosis around a single clinical goal: improving how gastritis is recognized before it becomes a more advanced and less reversible disease.